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I.History of Silicone Breast Implants and Their Regulation
Silicone breast implants ﬁrst appeared on the market over thirty years ago. well before the enactment of
The Medical Device Amendments of 1976. Thousands of women in the United States underwent surgery to
implant these medical devices into their bodies before the FDA even had any regulatory authority to require
a showing of safet or eﬃcacy. Today. an estimated one million women have silicone breast implants. Since
the 1976 Amendments, especially in the last ten years. complaints from women with implants have surfaced
in alarming numbers. Following a ﬂood of reports detailing adverse eﬀects from the silicone implants. the
FDA approved the proposed reclassiﬁcation of the implants as Class III devices. In July 1991. the FDA
required premarket approval of the implants. The FDA has power under Section 515(b) of the Federal Food.
Drug and Cosmetic Act to regulate preenactment Class III devices and their postenacrment equivalents by
requiring that they are approved for safety and eﬀectiveness.
Be’∼inning in 1988. the FDA requested information and scientiﬁc data about implants from the industry
and the medical profession, in an attempt to identify risks and beneﬁts of the devices. The response uncovered
several serious health concerns related to use of the implants, ranging from chest pain and infection to
autoimmune disorders and possible long-term toxic eﬀects of leaking silicone gel. Unfortunately, the data
produced left a lot of unanswered questions and uncertainty. In November 1991. an advisory committee
heard testimony about risks of implants from medical experts, and about beneﬁts from women who ar∼ued
1for the continued availabiltv of implants for both reconstruction and augmentation.1 The medical reports
were largely inconclusive, and the women’s testimony apparently had great emotional impact on the panel.
The committee recommended leaving the product on the market, despite the fact that safety and eﬃcacy
issues left unresolved.
On January 6, 1992. due to continuing complaints and concerns, a moratorium was placed on all silicone
breast implants pending further investigation into health risks. Again, the FDA requested information, and
received conﬂicing data and reports. Upon the recommendation of the advisory committee which met again
in Febraury 1992, the FDA proceeded to lift the moratorium in April 1992. Severe restrictions, however,
were placed on the use of implants. The FDA resolved to allow silicone breast implants for reconstructive
purposes, but to prohibit them for cosmetic use.
The FDA has received criticism for its decision regarding silicone breast implants. especially the seemingly
arbitrary distinction between the two types of use. This paper will attempt to examine whether the FDA was
justiﬁed in its decision, and whether a more eﬀective means was available to protect the health of women,
while respecting their right to choose.
II.Risks Associated with Silicone Implants
When the FDA gathered information regarding risks of silicone breast implants, it discovered what over
ten thousand women already knew. The implants leak and rupture, and often have to be removed because
of related medical problems. Women across the country reported chest pain, hardening of the implants, loss
of sensation in the breast and nipples, bleeding, infection. fever, skin conditions, dizziness, loss of sleep,
memory loss, and hair loss. On the more serious end of the spectrum are reports of soft tissue tumors,
1Mark A. Heller. Breast Implants: A Crisis Waiting to Happen, at 247.
2breast lumps, tissue disease, auto-immune disease and even death.2 Nlanv of these complaints have been
the impetus for over ten thousand lawsuits involving silicone breast implants ﬁled since 1981.
In addition to ﬁrst-hand reports, another source of information about the problems with breast implants
is found in the evaluation and summary prepared by the FDA.3 The signiﬁcant risks identiﬁed by the
FDA include: 1)ﬁbrous capsular contracture, (2) deﬂation, (3) infection, (4) interference with early tumor
detection. ∼5) human carcinogenicity, (6) human teratogenicity (producting a malformed fetus), (7) adverse
immunological eﬀects andor connetive tissue disorders, (8) calciﬁcation, and (9) biological eﬀects of silica.
Despite the fact that the FDA cited various scientiﬁc studies and referred to articles in medical journals,
it claimed that further clinical data was needed to make a risk. beneﬁt analysis. Once again, the FDA
announced that it was seeking more information.
III.Beneﬁts of Silicone Implants
Even with incomplete medical evidence concerning the adverse eﬀects of silicone implants on a woman’s
health, the risks of implants can be argued on a more objective level than the beneﬁts. FDA has adopted
the position that the beneﬁts of breast implants. whether for reconstruction or augmentation are purely
psychological.4 The eﬀectiveness of breast implants depends on the level of beneﬁt perceived by the woman
seeking them, and varies froem patient to patient. Thus, the subjective nature to the beneﬁts associated
with the implants are diﬃcult to assess, particularly for the purpose of balancing against risks which include
severe physical harm.
As medical devices, silicone breast implants are clearly distinguishable from devices such heart valves
or dialysis machines which clearly oﬀer substantial medical beneﬁts. Supporters would be hard-pressed to
2See Health Device Alert database, Westlaw.
35SFed.Reg.3436(Januarys, 1993)
4Id. at 3439
3come up with an argument that a breast implant could save a woman’s life.5 Rather, implants are valued
for their cosmetic eﬀect – whether replacing a breast that has been removed or enlarging a breast that
is considered too small. This cosmetic eﬀect does seem to beneﬁt many women by improving self-esteem,
building selfronﬁdence, alleviating feelings of inadequacy or unattractiveness. and reducing depression. Not
surprisingly, the FDA has suggested the need for scientiﬁc documentation of the psychological beneﬁts of
implants. If controlled clinical studies could be undertaken, and more objective standards of beneﬁt produced,
the FDA and women considering implantation could better analyze the risks and beneﬁts of the devices.
IV.Analysis of the FDA Decision
When the FDA decided to restrict the availability of silicone breast implants, it set the stage for a
continuing debate which has left no line of argument unexplored. Morality, free choice, medical knowledge,
social constructs and political inﬂuence have all played roles in the aftermath of the decision.
A.Why the Distinction?
One of the most troubling aspects of the FDA decision was the seemingly arbitrary distinction drawn
between the silicone implants used for reconstruction and those used for augmentation. Implantation is an
elective procedure in both situations, and the risks created by the implants exist regardless of the reasons
a woman chooses to undergo surgery. This section will explore some possible justiﬁcations for treating the
two types of use diﬀerently.
The FDA rejected an argument that breast reconstruction patients can accept greater long-term risks
than augmentation patients.6 Although the source and reasoning behind this argument were not revealed, it
5Although some women claim that but for availability of breast implants, they would have refused to submit to radical
mastectomies. My own great-aunt, an exotlc dancer in the days before breast implants had appeared on the market, died of
breast cancer because she refused the surgery.
656 Fed. Reg. 14620 (April 10, 1991)
4most likely evolved from the idea that women seeking augmentation are generally younger and healthier than
women seeking reconstruction. Thus, the risks for augmentation candidates could be viewed as more serious
because of the higher likelihood of prolonged exposure to the implants. Women who undergo reconstruction,
on the other hand, are generally older and have already gone through the trauma of a major surgery and a
major disease. The possibility of developing an auto-immune disorder in the indeﬁnite future might mean
little to them. In a sense, they could be seen as having nothing to lose.
The FDA was wise to dismiss this argument. Not only does the assertion over-generalize about the
characteristics of implant candidates, but the same reasoning suppports the conclusion that reconstruction
patients are less able to accept long-term risks of breast implants than augmentation candidates. These
women might be more susceptible to long-term risks, especially auto-immune disorders, exactly because
they have already submitted to major surgery and have been left weakened by the trauma. Further, it is
illogical to argue that a woman who has already been through a life-threatening ordeal will casually accept
additional nsks that a woman seeking augmentation would reject.
Despite rejecting a long-term risk diﬀerential, and agreeing that the short-term risks are the same for both
categories, the FDA maintained thatthe risk/beneﬁt analyses for breast reconstruction and augmentation
patients diﬀer.7 If the health risks are generally the same, it must be the beneﬁts that necessitate the
diﬀerent analyses urged by the FDA.
Since the beneﬁts of breast implants are purely psychological for both categories of patients, any diﬀerence
must be one of degree. The beneﬁt received by a particular woman will depend on subjective factors such
as her perceived need for the implants, her satisfaction with the results of the surgery, and the improvement
in her psychological state from before to after the surgery. The FDA believes that the function of the device
756 Fed. Reg. 14620, 14625 (April 10, 1991)
5will play a role in the level of beneﬁt.8
Surely the beneﬁts of breast implants will vaxy even among women in a given category. For instance, the
beneﬁts of augmentation for a woman who is terribly unhappy with her body image and the beneﬁts to an
exotic dancer who stands to enlarge her salary by enlarging her breasts are surely diﬀerent. And yet, each of
these women might value the implants even more than a woman seeking reconstructive surgery. Again, the
problem is subjectivity. How does one measure beneﬁt to an individual when there is no basis of comparison?
Would the FDA agree to a system in which women could have access to breast implants for augmentation
as long as they could show a threshhold of beneﬁt at least equal to the beneﬁt received by women in the
reconstruction category?
The panel advising the FDA in November 1991 could not distinguish between the needs of women who
pursued reconstruction and those who wanted augmentation.9 Just a few months later, the panel urged
the FDA to prohibit breast implants for augmentation, drawing a distinction based on intended use for the
devices. The change of heart could have been purely political. Anecdotal testimony from women satisﬁed
with their cosmetic implants was heard at the ﬁrst meeting of the advisory panel. They were not included
in the second meeting. Further, FDA Commissioner David Kessler was reportedly unhappy with the panel’s
original advice. Could his personal dislike for plastic surgery have been the impetus behind the FDA
decision?10
There is no discernable diﬀerence in risk between reconstruction implants and augmentation implants,
and a distinction between the beneﬁts is impossible to determine. Thus, a social or moral judgment could
858 Fed. Reg. 3436, 3441 (January 8, 1993) - The FDA also recognizes the subjective and transient nature of beneﬁts based
partially on patient expectations.
9Mark A. Heller. Breast Implants: A Crisis Waiting to Happen, at 247.
10FDA Insider Peter Barton Hurt tells Harvard Law School class that Kessler views plastic surgery as selr-mutilation, January
∼O, 1995.
6be the only true distinction separating the two uses. The American Society of Plastic and Reconstructive
Surgeons condemned the FDA for regulating implants on the basis of morality.11 Regardless of the truth of
the accusations. Mr. Kessler would not be the ﬁrst to have associated breast augmentation with burlesque
and to discount the procedure as frivolous.12 Because many augmentation candidates do work in the sex
industry, a certain stigma is associated with breast enlargements, especially those of unusually large size.
However, according to an FDA estimate, eighty percent of breast imolantations were performed for the
ourDose of augmentation.13 Surely these were not all requested by performers. Plenty of ordinary women
desire augmentation for reasons other than economic gain. To reduce their desires to something frivolous
or immoral trivializes the importance of mental health and deprives some women from feeling good about
themselves. The FDA made a mistake by banning silicone breast implants for one purpose but not another.
If the devices are truly unsafe and ineﬀective, they should be banned for all purposes. If not, there should
be no limitations, especially those justiﬁed only by one man’s beliefs ´ o even if he is the Commissioner.
B.What About Choice ?
Although the FDA would have better served the interests of women by adopting an all or nothing
approach, it is not absolutely clear which option should have been pursued ´ o the all or the nothing. Would
women be better oﬀ having the opportunity to choose whether breast implants are right for them despite the
possible risks, or are women in need of protection against misinformation and external forces? This section
will review the arguments for and against a ban on silicone breast implants for any purpose.
11At an April 16, 1992 press conference, ASPRS President Norman Cole, M.D. stated, We continue to be disappointed that
the government has placed itself in the role of judging the morality of a woman’s reasons for choosing breast impl∼∼... The
needs of women who seek augmentation of their breasts are poorly understood by those who do not share this desires. Reported
in the Gray Sheet, April 20, 1992.
12Mark A. Heller. Breast Implants: A Crisis Waiting to Happen, at 247.
1356 Fed. Reg. 49098 (September 26, 1991)
7The strongest argument against banning silicone breast implants altogether is that it severely restricts the
choice of women who desire them for any purpose. Beneﬁts from a cosmetically improved body image are not
trivial. Uke it or not, attractive people do gain certain advantages in a society that values superﬁcial beauty.
Further, a woman’s decision eﬀects no one but herself, so if she makes a personal risk/beneﬁt analysis and is
willing to accept the risks associated with implants, it seems that the government has no place telling her no.
A complete ban on implants is paternalistic and assumes women cannot sort out the available information
and decide for themselves.
A ﬁrst response to this argument is that paternalism is inherent in regulation. Sometimes the government
must substitute its judgment for the protection of people who for some reason are likely to misjudge the
harms associated with a certain activity. An example is in the case of illegal drugs.
A second and more signiﬁcant response is that FDA regulation is needed in the case of breast implants
to substitute for a lack of information. The premise of the argument against banning is that women should
be able to make an informed choice. If the choice is not informed, it is not really free at all. A number of
factors eﬀect the availability of information in the implant context. First, there are still many unanswered
questions about the actual health risks involved. Second, societal messages about body shape act as an
undue inﬂuence on women’s choice. Third. implant manufacturers and plastic surgeons can exert subtle, or
not-so-subtle pressure on women to choose implantation. All of these factors inhibit the choices avaiable to
women and call for government regulation as a counterbalance.
The FDA requires that prospective implant patients be given information about risks associated with
the implants. In March 1989. the FDA announced the development of an educational program to assure
that women considering surgical implantation of breast prostheses are fully informed of the beneﬁts and
8risks associated with the devices before consenting to the surgical procedure.14 Again in September 1991 the
FDA issued a Federal Register notice requiring dissemination of information on risks associated with silicone
implants.15 This time the FDA threatened manufacturers with a charge of misbranding under Section 502(a)
of the Food, Drug and Cosmetic Act if the correct information is not included. The FDA asserted that it
is crucial for women contemplating implantation to be provided with information on the known, suspected,
and potential risks associated with these devices.
Despite this requirement of information to women, the goal envisioned by the FDA has still not been met
because of unanswered questions concerning the medical risks. In FDA hearings regarding silicone breast
implants, a certain pattern emerges. Health problems related to the implants are reported as potential risks;
the FDA requests more information, scientiﬁc documentation and clinical studies; the results are incomplete
or inconclusive; the process starts all over again. Perhaps the repeated requests for information are a signal
as to the root of the information problem. Having been around for only a little over thirty years, and with
little or no studies done before marketing, many long term eﬀects of the implants are not yet known, and will
not be until women with implants are tracked from the moment of implantation, and evaluated over time for
the eﬀects of prolonged contact with the silicone shell. This obviously will take some time ´ o but surely by
now a signiﬁcant number of wonien could have been subject to studies for long-term eﬀect. Safety concerns
were brought to the attention of the medical profession in the early 1980s. Nearly ﬁfteen years later, there
are still no clear scientiﬁc answers.
The known and potential risks associated with implants are not insigniﬁcant. Auto-immune disease and
carcinogenicity are serious concerns. Opponents of an FDA ban, however, stress a lack of medical evidence
linking these health problems with breast implants. In 1991, the ﬁrst advisory panel heard testimony from
14∼ Fed. Reg. 10729 (March 15, 1989)
1556 Fed. Reg. 49089 (September 26, 1991)
9scientists and physicians who found no correlation between silicone breast implants and signiﬁcant health
risks.16 As recently as mid-1994, the New England Jourani of Medicine published a study completed at the
Mayo Clinic which showed no link between silicone gel implants and auto-immune disease.17 Anti-implant
arguments, however will point out that the clinical signiﬁcance of the study’s conclusion is in question because
of the size of study. Also, a more cynical rebuttal is to analogize the studies to those oﬀered by the tobacco
industry to show no correlation between smoking and lung cancer.
Another source of misinformation limiting women’s ability to choose is the media. During the height of
the breast implant crisis, the media added to the confusion by giving conﬂicting reports on the safety of
implants. Reporters either ignored or didn’t understand medical issues well enough to be helpful to women.18
Reporting health news is not the only role the media has played in the breast implant debacle. Societal
messages sent by the media tell women that they should look like models in magazines and actresses on
television and in the movies. Since most women are not born looking like super-models. they are pressured
to alter their bodies to measure up. The psychological beneﬁts of breast implants are primarily the result
of a conditioning of women to believe that they are unattractive if they do not have large breasts (among
other things). The FDA reported that [slome studies have shown that women seeking breast enlargement
are individuals who feel phsycially indadequate, with doubts concering their femininity and desirability.19
With feelings like these, which are intensiﬁed by constant media images of the right body shape, it is no
wonder women don’t receive respond to available information, and are willing to disregard signiﬁcant health
risks in order to get implants. While changing societal messages is a job too big for the FDA, it could help
combat the resulting eﬀects on women by banning the devices they are encouraged to use.
16Mark A. Heller. Breast Implants: A Crisis Waiting to Happen, at 247
17Josh Feldstein. Breast Implants: Can a Medical Communications Crisis Be Managed? at 255-256
18Id. at 255
1958 Fed. Reg. 3436, 3439 (january 8, 1993)
10The third factor that interferes with truly free choice by women is propaganda produced by implant
manufacturers and plastic surgeons. These two groups obviously have a vested interest in persuading women
that they need breast implants. Some of the tactics used are ethically questionable. For instance, in I$83,
the American Society of Plastic and Reconstructive Surgeons (ASPRS) invested four million dollars in a
public relations campaign encouraging the use of breast implants.20 The ASPRS compiled brochures which
included before and after photographs and represented that cosmetic surgery was safe and inexpensive. The
organization also made statements to the eﬀect that ﬂat-chestedness leads to a general lack of well-being and
speaking of small breasts, said these deformities are really a disease. This kind of campaign is outrageous. It
preys on the insecurities of women and pressures them to undergo painful, risky surgery with false reassurance
of safety. The ASPRS also downplays the cosmetic nature of the surgery by conjuring up images of disease.
This kind of advertising should be banned regardless of whether the implants themselves are prohibited.
Finally, proponents of choice argue that banning silicone breast implants is unfair and unwise because safe
alternatives do not exist. The response to this argument is two-fold. First, there are a number of alternatives
currently availabe. Second, more alternatives might be researched and developed if silicone implants were
banned for all purposes.
The most viable alternative to silicone gel-ﬁlled breast implants are saline-ﬁlled implants. They are
most similar to the silicone variety in that they are internal prostheses that give the appearance of a real
breast. The drawback to saline implants is a cosmetic one. Apparently, they do not feel as genuine as
silicone implants. Healthwise, however, the saline implants have an advantage. They are safer than silicone
implants because the salt water inside is not harmful to the body if the implant leaks or ruptures. This is
an improvement over the silicone gel ﬁlling which causes many of the health problems with implants. Saline
20Rebecca Weisman. Reforms in Medical Device Deregulations: An Examination of the Silicone Breast Implant Debacle. 23
Golden Gate U. LRev. 973.
11implants are currently under FDA review. Potential risks associated with the silicone enclosure are being
studied. According to the FDA Talk Paper of December 23, 1994, studies have been proposed through 1998,
and information, including preclinical data will be required from the manufacturers of the saline implants.
The FDA has also announced that it is seeking information on other alternatives to implants containing
silicone.21 It has invited scientiﬁc authorities to discuss issues of safety and eﬀectiveness, new technology and
testing requirements for new devices. Hopefully this attempt will be successful, but some manufacturers may
be leery of the long approval process and the potential liability unless silicone implants have been eliminated
as competition.
V.Conclusion
The arguments on both sides of the debate are compelling. The breast implant crisis has raised serious issues
for women. One one hand, it is diﬃcult to argue against giving women the right to choose, especially when
the choice involves their own bodies. Restricting freedom in that realm is politically unpopular these days.
On the other hand, women have been harmed by the lack of conclusive health information and by deceptive
and coercive messages sent by media, implant manufacturers and plastic surgeons.
For women to beneﬁt from their right to choose, they must have more accurate and complete information.
The conﬂicting studies currently available are insuﬃcient to form the basis of an informed choice. In addition
to medical information, women should also be given information about the psychological motivations behind
21∼ Fed. Reg. 48330,4833 1
12cosmetic surgery. Women should be reminded that they are not freaks or diseased if they have small breasts.
Other means of gaining self-esteem and conﬁdence should be explored before the drasitic decision to go
under the knife is made. Finally, sources of misleading or deceptive information that results in harm to
women should be punished. The Federal Trade Commission does have the authority to monitor advertising
which makes claims about speciﬁc cosmetic procedures, but nothing short of social reform will combat the
misperception that all women must look like models to lead satisfying, fulﬁlled lives. The role of regulation
is important in protecting against societal myths and their resulting harms. Unless women can gain access
to the whole story, the FDA should ban breast implants for all purposes in the name of the health and
happiness of women.
13